1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. Summary
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  01:44 2022-08-11 am EDT
0.0260 AUD    0.00%
08/10Patrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
08/05/2022 08/08/2022 08/09/2022 08/10/2022 08/11/2022 Date
0.025(c) 0.025(c) 0.024(c) 0.026(c) 0.026 Last
875 435 1 786 026 373 432 5 538 432 1 257 209 Volume
0.00% 0.00% -4.00% +8.33% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2020 0,77 M 0,55 M 0,55 M
Net income 2020 -2,75 M -1,95 M -1,95 M
Net cash position 2020 3,98 M 2,82 M 2,82 M
P/E ratio 2020 -4,68x
Yield 2020 -
Sales 2021 1,34 M 0,95 M 0,95 M
Net income 2021 -4,06 M -2,88 M -2,88 M
Net cash position 2021 10,9 M 7,74 M 7,74 M
P/E ratio 2021 -22,2x
Yield 2021 -
Capitalization 53,5 M 37,9 M 37,9 M
EV / Sales 2020 11,5x
EV / Sales 2021 67,8x
Nbr of Employees 10
Free-Float 70,9%
More Financials
Company
Patrys Limited is an Australia-based company, which is engaged in the development of antibody therapies for the treatment of cancer. The Company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in... 
More about the company
All news about PATRYS LIMITED
08/10Patrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
07/04Patrys Produces Antibody Drug at Commercial Scale
MT
07/03Patrys Limited Announces Successful Completion of Pat-Dx1 Engineering Run
CI
06/14Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody
MT
06/03Patrys Secures Grant Funding to Develop Brain Cancer Drug
MT
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
PU
04/14PATRYS : Application for quotation of securities - PAB
PU
03/23NEW RESEARCH : Scientists determine structure of a DNA damage ‘First Responder' prot..
PU
02/27Patrys Limited Announces Stable Cell Line for Production of PAT-DX3
CI
02/24PATRYS : Appendix 4D - Half Year Accounts - 31 December 2021
PU
02/24Patrys Limited Reports Earnings Results for the Half Year Ended December 31, 2021
CI
02/07PATRYS : Application for quotation of securities - PAB
PU
02/07PATRYS : ADC Deals Making Headlines
PU
More news
News in other languages on PATRYS LIMITED
08/10Patrys valide l'efficacité d'un médicament contre le cancer du cerveau dans une étude p..
07/04Patrys produit un médicament anticorps à l'échelle commerciale
07/03Patrys Limited annonce l'achèvement réussi de l'essai d'ingénierie du Pat-Dx1
06/03Patrys obtient une subvention pour développer un médicament contre le cancer du cerveau
02/27Patrys Limited annonce une lignée cellulaire stable pour la production de PAT-DX3
More news
Chart PATRYS LIMITED
Duration : Period :
Patrys Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PATRYS LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Managers and Directors
James A. Campbell Chief Executive Officer, MD & Director
John Douglas Read Non-Executive Chairman
Valentina Dubljevic Vice President-Scientific & Clinical Development
Michael J. Stork Deputy Chairman & Non-Executive Director
Suzy Jones Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PATRYS LIMITED-29.73%38
MODERNA, INC.-31.38%68 174
LONZA GROUP AG-26.76%44 940
IQVIA HOLDINGS INC.-15.05%44 704
SEAGEN INC.13.62%32 396
ALNYLAM PHARMACEUTICALS, INC.36.81%27 846